Qiming Venture Partners and Nearly 40 Portfolio Companies Named to VBData 2026 Future Healthcare 100
China's most authoritative and influential innovation benchmark for the healthcare industry
Recently, VBData announced its 2026 Future Healthcare 100 rankings, which include the 2026 Future Healthcare 100 list and the 2026 Future Healthcare 100 awards. Qiming Venture Partners and nearly 40 of its portfolio companies were selected.
Qiming Venture Partners was named to the Top 50 Value Investment Firms in China's Healthcare Industry, and William Hu, Managing Partner at Qiming Venture Partners, was named to the Top 50 Innovation Influencers in China's Healthcare Industry. Qiming portfolio companies and entrepreneurs recognized include: Jieti Medical, Shukun Technology, Cornerstone Robotics, Dingke Medical, Tingsheng Technology, Wanzhong Yixin, VINNO, Wushuang Medical, RuiNing Bio, Pushi Lihua, Shengzhe Medical, Origincell, Ark Biosciences, Minghui Medical, Zenitar, Zhitai Bio, Shize Biotech, Tianchen Bio, EpiJan Therapeutics, Yuanxin Technology, BioLink, MUMU Fertility, Benyao Technology, Zhilan Health, Inscinstech, Temedical, Torus AI, InventisBio (688382.SH), Tigermed (300347.SZ, 03347.HK), Pulnovo Medical, Tupu Medical, Aohua Endoscopy (688212.SH), Jialiang Brain Science, Ze'an Biopharmaceutical, Insilico Medicine (03696.HK), Northsea Lifesciences (688712.SH), and others.
The 2026 Future Healthcare 100 rankings focus on pioneering entities that drive efficient circulation of innovative assets, catalyze the realization of "China-first" breakthroughs, and set the direction for global investment value — at a new starting point for industrial innovation, continuously uncovering breakthrough practices in new technologies, new transactions, and new ecosystems.
Qiming Venture Partners
Awarded
Top 50 Value Investment Firms in China's Healthcare Industry
William Hu, Managing Partner at Qiming Venture Partners
Awarded
Top 50 Innovation Influencers in China's Healthcare Industry — Influential Investor
Jieti Medical, Shukun Technology
Cornerstone Robotics, Dingke Medical, Tingsheng Technology
Wanzhong Yixin, VINNO, Wushuang Medical
RuiNing Bio, Pushi Lihua, Shengzhe Medical
Awarded
2026 Future Healthcare 100
Top 100 Innovative Devices and Intelligent Manufacturing
Origincell, Ark Biosciences
Minghui Medical, Zenitar, Zhitai Bio
Shize Biotech, Tianchen Bio, EpiJan Therapeutics
Awarded
2026 Future Healthcare 100
Top 100 Innovative Pharmaceuticals and Biological Products
Yuanxin Technology, BioLink
MUMU Fertility, Benyao Technology, Zhilan Health
Inscinstech, Temedical, Torus AI
Awarded
2026 Future Healthcare 100
Top 100 Innovative Health Services and Industry Chain Services
InventisBio
Awarded
2026 Top 50 Listed Healthcare Companies by Innovation Strength
Tigermed
Awarded
2026 Top 50 Listed Healthcare Companies by Overseas Expansion Strength
Cornerstone Robotics, Pulnovo Medical, Tupu Medical
Awarded
Top 50 Most Investment-Worthy Companies in China's Healthcare Industry
Aohua Endoscopy ERCP Surgical Robot
Jialiang Brain Science MRI-Guided Semiconductor Laser Therapy Device
Awarded
Top 50 Most Innovative Products and Technologies in China's Healthcare Industry — Intelligent Medical Device Technology
Ze'an Biopharmaceutical U-MCE™ (Universal Myeloid Cell Engager) Technology Platform
Awarded
Top 50 Most Innovative Products and Technologies in China's Healthcare Industry — Biotechnology
Feng Ren, Co-CEO, Chief Scientific Officer, and Head of Drug Discovery at Insilico Medicine
Song Liang, Chairman, General Manager, and CEO of Northsea Lifesciences
Awarded
Top 50 Innovation Influencers in China's Healthcare Industry — Influential Entrepreneur
Song Yangzhou, Founder of Pushi Lihua and Professor at Sun Yat-sen University's School of Life Sciences
Awarded
Top 50 Innovation Influencers in China's Healthcare Industry — Influential Scientist
Selection Criteria
2026 Future Healthcare 100 Non-Listed Companies Rankings
This ranking targets non-listed companies in the healthcare sector. Based on the VB100 valuation assessment model, the selection process involves company self-nomination, VB100 review committee evaluation, cross-review by supporting institutions, and final review by the expert committee. From three major categories — innovative devices and intelligent manufacturing, innovative pharmaceuticals and biological products, and innovative health services and industry chain services — the top 100 non-listed companies by valuation are selected. Beyond valuation, the evaluation also examines candidates' growth and annual performance across four primary indicators and 17 secondary indicators: human resources, knowledge resources, key partnership resources, and market performance.
Listed Companies Innovation Strength Rankings
This ranking targets listed companies in the healthcare sector. The list constructs the VB100 Listed Companies Innovation Strength Index around six key metrics: market capitalization and annual growth, innovative business revenue and annual growth, and R&D expenditure and annual growth. Through data analysis, it aims to reveal companies' capital value and strategic innovation capability, market value and commercial innovation capability, and technological value and product innovation capability — providing in-depth analysis of innovation value and growth momentum to identify benchmark enterprises with high innovation capacity and strong growth performance driven by innovation.
Listed Companies Overseas Expansion Rankings
This ranking targets listed companies in the healthcare sector. The list constructs the VB100 Listed Companies Overseas Expansion Strength Index around three core metrics: overseas revenue amount, overseas revenue as a percentage of total revenue, and year-over-year overseas revenue growth. Through data analysis, it aims to reveal companies' overseas revenue scale, overseas revenue contribution, and overseas revenue growth momentum — providing in-depth analysis of overseas expansion value and development trends to identify benchmark enterprises with strong overseas revenue capability and sustained growth performance.
Top 50 Innovation Influencers
Covering a diverse range of innovation-focused individuals with entrepreneurs, investors, and scientists as core selection targets, the evaluation dimensions include both personal innovation practices in technology, business, and capital and their industry radiating power, as well as the ecological influence of synergies between different roles in driving industrial innovation and upgrading. The selection aims to break down role barriers, precisely identify and recognize core figures playing key influential roles across the full chain of industrial innovation, and establish benchmark figures that are referenceable and replicable for collaborative innovation in the healthcare industry.
Top 50 Value Investment Firms
Focusing on the full-chain growth needs of innovative healthcare assets, with core coverage of value investment institutions, this selection identifies institutions' value-added service capabilities in capital injection, resource linkage, and strategic synergy with enterprises — ultimately providing a quality institutional cooperation reference of "capital empowerment" for the value release of innovative healthcare assets.
Top 50 Most Investment-Worthy Companies
Conducted with "innovation advancement as the core and investment value as the orientation," this selection provides capital markets with full-cycle quality options covering both "mature targets + potential targets," while also establishing "innovation implementation benchmarks at different development stages" for the healthcare industry. It simultaneously helps listed companies connect with industrial resources and strengthen industry influence, and assists non-listed companies in accessing capital and accelerating the commercialization of innovative achievements.
Top 50 Most Innovative Products and Technologies
Anchored in the dual value of "China-original + global breakthrough," this selection covers China-first and China-original products and solutions in three major fields: biotechnology, digital technology, and intelligent medical device technology. On one hand, it centrally presents China's top achievements in these areas of medical innovation, establishing industry benchmarks for "China-first" breakthroughs. On the other hand, it helps these breakthrough products connect with clinical resources, industrial cooperation, and global channels, accelerating the progression from "China-first launch" to "global application" and further strengthening the international influence of China's medical innovation.
Over ten years of deep cultivation, the Future Healthcare 100 rankings have become a highly credible and influential innovation evaluation benchmark in China's healthcare industry. For a decade, it has remained rooted at the front lines of the industry, closely following healthcare innovation development trends, continuously refining its evaluation system, and gradually expanding into a comprehensive ecosystem evaluation system covering innovative enterprises, leading figures, investment and service institutions, industry empowerment platforms, and innovative technology products — fully witnessing and participating in the growth and upgrading of China's healthcare innovation ecosystem.
Source | VBData
Past Reviews
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.16, 2026.5.12
Qiming Honors | 5 Qiming Venture Partners Investors Named to 2025 Forbes China Midas List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Hope Medicine, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.